Spero Therapeutics’ (NASDAQ:SPRO) “Buy” Rating Reiterated at Oppenheimer

Spero Therapeutics (NASDAQ:SPRO)‘s stock had its “buy” rating restated by research analysts at Oppenheimer in a report released on Tuesday, March 20th.

Other equities analysts have also recently issued reports about the stock. Zacks Investment Research cut shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Bank of America started coverage on shares of Spero Therapeutics in a research report on Monday, November 27th. They set a “neutral” rating on the stock. Cantor Fitzgerald started coverage on shares of Spero Therapeutics in a research report on Thursday, February 8th. They set an “overweight” rating and a $27.00 price target on the stock. Cowen started coverage on shares of Spero Therapeutics in a research report on Monday, November 27th. They set an “outperform” rating on the stock. Finally, ValuEngine raised shares of Spero Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. Spero Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $24.25.

How to Become a New Pot Stock Millionaire

SPRO stock traded up $2.86 during midday trading on Tuesday, reaching $17.85. The company’s stock had a trading volume of 54,161 shares, compared to its average volume of 32,518. Spero Therapeutics has a 52 week low of $9.66 and a 52 week high of $19.00. The stock has a market cap of $212.66 and a PE ratio of -1.00.

Spero Therapeutics (NASDAQ:SPRO) last announced its quarterly earnings data on Monday, April 2nd. The company reported ($1.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.77) by $0.18. The business had revenue of $0.99 million during the quarter, compared to the consensus estimate of $0.40 million. analysts forecast that Spero Therapeutics will post -4.94 EPS for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. TIAA CREF Investment Management LLC acquired a new stake in shares of Spero Therapeutics during the fourth quarter worth $103,000. California State Teachers Retirement System acquired a new stake in shares of Spero Therapeutics during the fourth quarter worth $112,000. Dean Capital Investments Management LLC acquired a new stake in shares of Spero Therapeutics during the fourth quarter worth $118,000. Deutsche Bank AG acquired a new stake in shares of Spero Therapeutics during the fourth quarter worth $155,000. Finally, California Public Employees Retirement System acquired a new stake in shares of Spero Therapeutics during the fourth quarter worth $294,000. 46.28% of the stock is currently owned by institutional investors.

WARNING: “Spero Therapeutics’ (NASDAQ:SPRO) “Buy” Rating Reiterated at Oppenheimer” was first published by Macon Daily and is owned by of Macon Daily. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://macondaily.com/2018/04/12/spero-therapeutics-spro-given-buy-rating-at-oppenheimer-updated-updated-updated-updated-updated.html.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections.

Analyst Recommendations for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply